

CT koronarografie a chronická ICHS



Jan Baxa

Klinika zobrazovacích metod, FN Plzeň a LF UK v Plzni

CT angiografie




European Heart Journal (2024) **00**, 1–123
European Society of Cardiology <https://doi.org/10.1093/eurheartj/ehae177>

ESC GUIDELINES

2024 ESC Guidelines for the management of chronic coronary syndromes


Developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC)

CT a chronická ICHS



Jan Baxa, Jiří Ferda

Klinika zobrazovacích metod, FN Plzeň a LF UK v Plzni



In CCS patients with symptoms refractory to medical treatment, and who have had previous coronary revascularization, CCTA should be considered to evaluate bypass graft or stent patency (for stents ≥ 3 mm).¹¹⁷⁴⁻¹¹⁷⁶

Ila

B

stenty a bypassy

jedno z prvních uplatnění CTA


větší rozměry
méně pohybových artefaktů


vysoká přesnost


100% senzitivita při hodnocení průchodnosti
93 - 100% senzitivita pro hodnocení stenozy

význam


po nekompletní SKG
před SKG / alternativa








stenozy




distální anastomóza



B 100 W 983
O 100 C 262

F

Computed Tomography Cardiac Angiography Before Invasive Coronary Angiography in Patients With Previous Bypass Surgery: The BYPASS-CTCA Trial

Daniel A. Jones , Anne-Marie Beirne, Matthew Kelham, Krishnaraj S. Rathod, Mervyn Andiapien, Lucinda Wynne, Thomas Godec, Nasim Forooghi, Rohini Ramaseshan, James C. Moon, Ceri Davies, Christos V. Bourantas, Andreas Baumbach, Charlotte Manisty, Andrew Wragg, Amrita Ahluwalia, Francesca Pugliese, Anthony Mathur and for the BYPASS-CTCA Trial Committees and Investigators

Originally published 29 Sep 2023 | <https://doi.org/10.1161/CIRCULATIONAHA.123.064465> | Circulation. 2023;148:1371–1380

Circulation

Volume 148, Issue 18, 31 October 2023; Pages 1371-1380
<https://doi.org/10.1161/CIRCULATIONAHA.123.064465>

randomizace

indikováni k SKG (600 subjektů)

preprocedurální CTA (1:1)

jedno centrum

jeden typ CT přístroje

bez selekce poruchy rytmu

outcome

délka SKG

spokojenost pacienta (skore)

kontrastní nefropatie

radiační zátěž, množství
kontrastní látky, komplikace
radiální přístupy, počet katetrů...

Computed Tomography Cardiac Angiography Before Invasive Coronary Angiography in Patients With Previous Bypass Surgery: The BYPASS-CTCA Trial

Daniel A. Jones, Anne-Marie Beirne, Matthew Kelham, Krishnaraj S. Rathod, Mervyn Andiapen, Lucinda Wynne, Thomas Godec, Nasim Forooghi, Rohini Ramaseshan, James C. Moon, Ceri Davies, Christos V. Bourantas, Andreas Baumbach, Charlotte Manisty, Andrew Wragg, Amrita Ahluwalia, Francesca Pugliese, Anthony Mathur and for the BYPASS-CTCA Trial Committees and Investigators


Originally published 29 Sep 2023 | <https://doi.org/10.1161/CIRCULATIONAHA.123.064465> | Circulation. 2023;148:1371–1380

Circulation

Volume 148, Issue 18, 31 October 2023; Pages 1371-1380
<https://doi.org/10.1161/CIRCULATIONAHA.123.064465>


Table 2. Invasive Coronary Angiography Procedural Data (Table view)

| Characteristics | CTCA+ICA (n=321) | ICA alone (n=342) | P value |
|--------------------------------|----------------------|-----------------------|---------|
| Radial access | 247 (76.9) | 194 (56.7) | <0.001 |
| Number of bypass grafts | | | |
| 1 | 23 (7.1) | 23 (6.7) | 0.34 |
| 2 | 82 (25.5) | 75 (21.9) | |
| 3 | 143 (44.4) | 177 (51.8) | |
| 4 | 65 (20.2) | 62 (18.1) | |
| 5 | 9 (2.8) | 5 (1.5) | |
| Mean±SD | 2.9±0.9 | 2.9±0.8 | |
| Procedure time, minutes | 18.6 (9.5) | 39.5 (16.9) | <0.001 |
| Fluoroscopy time, minutes | 8.1 (5.1) | 14.9 (7.5) | <0.001 |
| Radiation | | | |
| Air kerma, mGy | 121.0 (85.0–188.0) | 184.0 (124.8–301.0) | <0.001 |
| DAP, uGy ² | 770.0 (510.5–1136.0) | 1177.0 (827.0–1760.0) | <0.001 |
| Effective dose, mSV | 1.6 (1.0–2.4) | 2.6 (1.8–3.9) | <0.001 |
| Contrast, mL | 77.4 (49.1) | 173.0 (68.0) | <0.001 |
| Number of catheters during ICA | 3 (2–4) | 4 (3–5) | <0.001 |
| Mehran score | 7.2 (4.2) | 11.0 (5.5) | <0.001 |



koronární stenty

“blooming” artefakty




kalibr stentu



vývoj techní

poslední gen



Wan YL et al. Coronary in-stent restenosis: predisposing clinical and stent-related factors, diagnostic performance and analyses of inaccuracies in 320-row computed tomography angiography. *Int J Cardiol.* 2016





ORIGINAL ARTICLE



Open Access



stabilní AP

The effectiveness of coronary computed tomography angiography and functional testing for the diagnosis of obstructive coronary artery disease: results from the individual patient data Collaborative Meta-Analysis Cardiac CT (COME-CCT)

Peter Schlattmann¹, Viktoria Wieske², Keno K. Bressemer², Theresa Götz¹, Georg M. Schuetz², D. Gianluca Pontone³, Hatem Alkadhi⁴, Jörg Hausleiter⁵, Elke Zimmermann², Bernhard Gerber⁶, Abbas A. Shabestari⁷, Matthijs F. L. Meijs⁸, Akira Sato⁹, Kristian A. Øvrehus¹⁰, Shona M. M. Jenkinson¹¹, Juhani Knuuti¹², Ashraf Hamdan¹³, Bjørn A. Halvorsen¹⁴, Vladimir Mendoza-Rodriguez¹⁵, Johanna Yung-Liang Wan¹⁷, Christoph Langer¹⁸, Sebastian Leschka¹⁹, Eugenio Martuscelli²⁰, Said Ghossein²¹, Jean-Claude Tardif²², Alejandra Rodríguez Sánchez², Robert Haase² and Marc Dewey^{2,23,24*}



2024 ESC Guidelines for the management of chronic coronary syndromes

Recommendations for non-invasive anatomical imaging tests in the initial diagnostic management of individuals with suspected chronic coronary syndrome—coronary computed tomography angiography, if available, and supported by local expertise

In individuals with suspected CCS and low or moderate (>5%–50%) pre-test likelihood of obstructive CAD, CCTA is recommended to diagnose obstructive CAD and to estimate the risk of MACE.

I
A

CCTA is recommended in individuals with low or moderate (>5%–50%) pre-test likelihood to refine diagnosis if another non-invasive test is non-diagnostic.

I
B

Recommendations for selection of initial diagnostic tests in individuals with suspected chronic coronary syndrome

It is recommended to select the initial non-invasive diagnostic test based on pre-test likelihood of obstructive CAD, other patient characteristics that influence the performance of non-invasive tests, and local expertise and availability.

I
C

In symptomatic patients in whom the pre-test likelihood of obstructive CAD by clinical assessment is >5%, CCTA or non-invasive functional imaging for myocardial ischaemia is recommended as the initial diagnostic test.

I
B

To rule out obstructive CAD in individuals with low or moderate (>5%–50%) pre-test likelihood, CCTA is recommended as the preferred diagnostic modality.

I
B

CCTA is recommended in individuals with low or moderate (>5%–50%) pre-test likelihood if functional imaging for myocardial ischaemia is not diagnostic.

I
B

Recommendations for non-invasive anatomical imaging tests in the initial diagnostic management of individuals with suspected chronic coronary syndrome—coronary computed tomography angiography, if available, and supported by local expertise

In individuals with suspected CCS and low or moderate (>5%–50%) pre-test likelihood of obstructive CAD, CCTA is recommended to diagnose obstructive CAD and to estimate the risk of MACE.



| | |
|---|---|
| I | A |
|---|---|

CCTA is recommended in individuals with low or moderate (>5%–50%) pre-test likelihood to refine diagnosis if another non-invasive test is non-diagnostic.


| | |
|---|---|
| I | B |
|---|---|

CCTA is not recommended in patients with severe renal failure (eGFR <30 mL/min/1.73 m²), decompensated heart failure, extensive coronary calcification, fast irregular heart rate, severe obesity, inability to cooperate with breath-hold commands, or any other conditions that can make obtaining good imaging quality unlikely.

| | |
|-----|---|
| III | C |
|-----|---|



2024 ESC Guidelines for the management of chronic coronary syndromes



kalcifikace
arytmie
obezita
srdeční selhání
renální selhání




ESC
European Society
of Cardiology

European Heart Journal (2024) 00, 1–123
<https://doi.org/10.1093/eurheartj/ehae177>

ESC GUIDELINES

2024 ESC Guidelines for the management of chronic coronary syndromes



kalcifikace

arytmie

obezita

srdeční selhání

renální selhání





ESC
European Society
of Cardiology

European Heart Journal (2024) 00, 1–123
<https://doi.org/10.1093/eurheartj/ehae177>

ESC GUIDELINES

2024 ESC Guidelines for the management of chronic coronary syndromes



kalcifikace

arytmie

obezita

srdeční selhání

renální selhání

Recommendations for definition of high risk of adverse events

An initial stratification of risk of adverse events is recommended based on basic clinical assessment (e.g. age, ECG, anginal threshold, diabetes, CKD, LVEF).

The use of one or more of the following test results is recommended to identify individuals at high risk of adverse events:

- Exercise ECG:
 - Duke Treadmill Score < -10 ;
- stress SPECT or PET perfusion imaging:
 - Area of ischaemia $\geq 10\%$ of the LV myocardium;
- Stress echocardiography:
 - ≥ 3 of 16 segments with stress-induced hypokinesia or akinesia;
- stress CMR:
 - ≥ 2 of 16 segments with stress perfusion defects or ≥ 3 dobutamine-induced dysfunctional segments;
- CCTA:
 - left main disease with $\geq 50\%$ stenosis, three-vessel disease with $\geq 70\%$ stenosis, or two-vessel disease with $\geq 70\%$ stenosis, including the proximal LAD or one-vessel disease of the proximal LAD with $\geq 70\%$ stenosis and $\text{FFR-CT} \leq 0.8$.

| I | B |
|---|---|
| I | B |






“gaps in evidence” - subklinická AS

British Heart Foundation



THE SCOT-HEART 2 TRIAL




Researchers Unveil 10-Year Results Of Scottish CT Trial SCOT-HEART

Posted on [September 2, 2024](#)

After 10 years of follow-up, the research team found that coronary heart disease death or nonfatal myocardial infarction was lower in the CCTA group compared with the standard care group (n = 137, 6.6% vs. n = 171, 8.2%) and this was primarily driven by a reduction in myocardial infarction (n = 90, 4.3% vs. n = 124, 6%).

The team found no difference in all-cause mortality (n = 168, 8.1% vs. n = 166, 8%) or coronary revascularization between groups (n = 313, 15.1% vs. n = 317, 15.3%).



CCTA - “*first line*”?



ESC

European Society
of Cardiology

European Heart Journal (2024) 00, 1–123

<https://doi.org/10.1093/eurheartj/ehae177>

ESC GUIDELINE

2024 ESC Guidelines for the management of chronic coronary syndromes

technická stránka

rychlost / dostupnost
jednoduchost / bezpečnost

“kvalita”

NPV 92 % a více

hodnocení

kvantifikace stenózy
zpětná úprava dat
popis

